Queensland Melanoma Genomic Biomarker Study
|Study ID||Alternative Stable ID||Type|
There is a clinical need to identify melanoma patients not likely to benefit from current targeted and immuno-therapy and identify biomarkers that can predict patient outcome. Genomic biomarkers are not yet part of staging but show promising results. The aim of this study was to determine genomic and image-based biomarkers as adverse prognostic factors in stage III/IV melanoma patients with resected disease. We found combining genomic and PET/CT derived biomarkers with current clinical assessment may offer additional prognostic tools to stratify patients in the clinic.
Study Datasets 2 dataset.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
|EGAD00001006374||A study looking at Germline and Somatic biomarkers using WES data only||88|
|EGAD00001006375||A radiomics study integrating PET/CT, WES and RNAseq data||99|
Who archives the data?
Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients.
Sci Rep 10:2020 17687